Compare Adobe Systems Inc (ADBE) vs Ascendis Pharma A/S (ASND) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adobe Systems Inc vs Ascendis Pharma A/S — how do they compare? Adobe Systems Inc trades at $220.61 (market cap $88.06B), while Ascendis Pharma A/S trades at $277.16 (market cap $17.51B). The key difference: Adobe Systems Inc is far larger — about 5× Ascendis Pharma A/S's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Adobe Systems Inc nearer its low. Which is the better fit depends on your goals.
| ADBE | ASND | |
|---|---|---|
Market Cap | $88.06B | $17.51B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $382.24 | $274.50 |
52-Week Low | $193.41 | $163.32 |
Enterprise Value | $89.50B | $17.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe Inc. (ADBE) trades at $220.94, up 1.32% with strong fundamentals including 29.99% net margin and consistent earnings beats. Technical indicators show bullish momentum with support at $218 and resistance at $228. Recent news highlights institutional buying despite AI competition concerns, while cash flow remains robust at $10.03B from operations in 2025.
Outlook remains positive with a $246.75 analyst target, though risks include AI disruption and CEO transition. Valuation appears attractive with P/E of 12.67, supporting a buy case for long-term growth investors amid near-term volatility.
Ascendis Pharma (ASND) trades at $266.97, down 2.74% on the day. The stock maintains a bullish technical outlook with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, revenue growth is strong, reaching $720.13M in 2025, but the company remains unprofitable with a net loss of $228.03M. Recent positive clinical trial data for TransCon CNP and inclusion in Russell indexes highlight ongoing business momentum.
The outlook is optimistic, driven by analyst consensus and a $320 price target, but risks include persistent losses, high debt levels, and reliance on pipeline success. Near-term performance hinges on Q2 2026 earnings versus the $1.29 EPS expectation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →
